INSTRUCTIONS New drugs 2014, part 1
* To take the test online, go to our secure website at http://www.nursingcenter.com/ce/nursing.
* On the print form, record your answers in the test answer section of the CE enrollment form on page 55. Each question has only one correct answer. You may make copies of these forms.
* Complete the registration information and course evaluation. Mail the completed form and registration fee of $32.95 to: Lippincott Williams & Wilkins, CE Group, 74 Brick Blvd., Bldg. 4, Suite 206, Brick, NJ 08723. We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form.
* You will receive your CE certificate of earned contact hours and an answer key to review your results. There is no minimum passing grade.
* Registration deadline is February 29, 2016.
DISCOUNTS and CUSTOMER SERVICE
* Send two or more tests in any nursing journal published by Lippincott Williams & Wilkins together by mail, and deduct $0.95 from the price of each test.
* We also offer CE accounts for hospitals and other healthcare facilities on nursingcenter.com. Call 1-800-787-8985 for details.
Lippincott Williams & Wilkins, publisher of Nursing2014 journal, will award 4.0 contact hours for this continuing nursing education activity.
Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #FBN2454. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 4.0 contact hours.
Your certificate is valid in all states. This activity has been assigned 4.0 pharmacology credits.
The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers only to its continuing nursing educational activities and does not imply Commission on Accreditation approval or endorsement of any commercial product.
New drugs 2014, part 1
GENERAL PURPOSE: To provide information about 14 newly approved drugs. LEARNING OBJECTIVES: After reading this article and taking this test you should be able to: 1. Identify the indications for 14 new drugs. 2. Identify potential adverse reactions associated with 14 new drugs. 3. List nursing considerations for 14 new drugs.
1. Compared with warfarin, apixaban
a. has a higher rate of all-cause death.
b. has a higher rate of major bleeding events.
c. is superior for reducing the risk of systemic embolism.
d. is superior for reducing the risk of purely ischemic strokes.
2. Which statement about apixaban is correct?
a. It should be discontinued at least 48 hours before elective surgery with a high risk of unacceptable bleeding.
b. It should be discontinued 12 hours before elective surgery with a low risk of bleeding.
c. Vitamin K reverses apixaban-induced excessive anticoagulation.
d. Apixaban requires routine INR monitoring.
3. The recommended dosage of apixaban for an 82-year-old patient weighing 130 pounds (59 kg) is
a. 2.5 mg daily.
b. 2.5 mg twice daily.
c. 3.5 mg three times daily.
d. 5 mg twice daily.
4. Which statement about lomitapide mesylate is correct?
a. It's indicated to treat hypercholesterolemia in patients with HoFH.
b. It's indicated for patients with hypercholesterolemia without HoFH.
c. It's effective without dietary or other treatments to lower LDL-C.
d. In clinical studies, it was associated with a significant decrease in cardiovascular morbidity and mortality.
5. The subject of a boxed warning for lomitapide is
a. heart failure.
c. renal toxicity.
6. Which statement is correct about treatment with lomitapide?
a. About 50% of patients experience GI adverse reactions.
b. Patients should take the medication with food to decrease GI adverse reactions.
c. Patients should adhere to a low-fat diet.
d. The dosage should be rapidly increased to the maximum recommended dosage based on patient tolerance.
7. Teaching for women taking lomitapide should include all of the following except
a. Use reliable contraception during therapy.
b. Take the drug with food.
c. Take dietary supplements as prescribed.
d. Avoid grapefruit juice.
8. Which statement is correct about mipomersen?
a. It's administered as an adjunct to LDL apheresis.
b. It reduces LDL-C by 75% in the first 26 weeks of therapy.
c. It significantly reduces cardiovascular morbidity.
d. It's administered via subcutaneous injection.
9. Before a patient starts mipomersen, which blood test should be performed?
a. CBC count
b. coagulation profile
d. hepatic function panel
10. Mipomersen should be avoided in patients with all of the following conditions except
a. moderate hepatic impairment.
b. severe renal impairment.
c. cardiovascular disease.
d. alcohol use disorder.
11. The recommended dosage for mipomersen is
a. 200 mg daily.
b. 200 mg once a week.
c. 300 mg every other week.
d. 300 mg once a week.
12. Canagliflozin lowers blood glucose concentrations by
a. enhancing insulin secretion.
b. reducing reabsorption of filtered glucose.
c. reducing insulin resistance.
d. increasing the renal threshold for glucose.
13. Canagliflozin's action may be reduced by the concurrent use of all of the following drugs except
14. Which of the following statements about canagliflozin is correct?
a. It's associated with HPV infection.
b. It's contraindicated in patients with severe renal impairment.
c. It's approved only for use as monotherapy.
d. It may decrease serum digoxin levels.
15. Canagliflozin should be administered
a. before the first meal of the day.
b. at a starting dose of 300 mg twice daily.
c. up to a maximum daily dose of 600 mg.
d. before each meal.
16. Alogliptin is indicated for adults with
a. type 1 diabetes mellitus.
b. type 2 diabetes mellitus.
c. diabetic ketoacidosis.
17. A warning for alogliptin concerns
a. renal failure.
c. hepatic failure.
18. Teach patients taking alogliptin that
a. they should undergo kidney function testing before beginning therapy and periodically thereafter.
b. each dose should be taken with food.
c. the drug raises the risk for heart rhythm problems.
d. if they miss a dose, they should double the next dose.
19. Ospemifene is indicated to treat
b. moderate to severe dyspareunia due to menopause.
c. endometrial cancer.
d. post-menopausal osteoporosis.
20. The subject of a black box warning for ospemifene concerns an increased risk for
a. endometrial cancer.
b. breast cancer.
d. myocardial infarction.
21. Ospemifene is not contraindicated in women with
b. breast cancer.
c. active DVT.
22. Tell patients taking ospemifene to
a. report unusual insomnia.
b. take each dose on an empty stomach.
c. report unusual vaginal bleeding.
d. expect to experience some minor bruising.
23. Which of the following statements about lorcaserin is correct?
a. It activates serotonin 2B receptors.
b. It's an anorexiant.
c. It's a combination of two older medications.
d. It affects receptors in the pituitary gland.
24. Lorcaserin is indicated for chronic weight management in adults with an initial BMI of at least
a. 25 kg/m2.
b. 27 kg/m2.
c. 29 kg/m2.
d. 30 kg/m2.
25. Precautions for the use of lorcaserin include all of the following except
b. serotonin syndrome.
c. suicidal ideation.
26. Which statement about lorcaserin is correct?
a. It's classified as a Schedule IV controlled substance.
b. It's safe to use during pregnancy.
c. Treatment should be combined with a serotonin 2B receptor agonist.
d. It's recommended for patients with severe renal dysfunction.
27. Dimethyl fumarate is indicated to treat
a. multi-drug resistant tuberculosis.
b. diarrhea in patients treated for HIV/AIDS.
c. relapsing forms of multiple sclerosis.
d. type 2 diabetes.
28. Dimethyl fumarate is known to decrease
a. serum estrogen levels.
b. lymphocyte counts.
c. red blood cell counts.
d. blood glucose levels.
29. Patients taking dimethyl fumarate should
a. discard unused capsules 60 days after opening the bottle.
b. undergo a creatinine clearance test before treatment begins.
c. obtain a lipid panel within 6 weeks after beginning treatment.
d. stop treatment if a serious infection develops.
30. The initial dosage of dimethyl fumarate is
a. 60 mg daily.
b. 120 mg daily.
c. 120 mg twice a day.
d. 240 mg twice a day.
31. Bedaquiline is indicated
a. as combination therapy for multi-drug-resistant (MDR) pneumonia.
b. for adults with pulmonary MDR-TB.
c. as monotherapy for adults with extra-pulmonary TB.
d. for children with TB meningitis.
32. The risk of bedaquiline-induced QT prolongation is increased in patients with
c. type 2 diabetes.
d. uncompensated heart failure.
33. Common adverse reactions to bedaquiline include
a. muscle spasms.
34. Crofelemer is indicated in adults with HIV/AIDS on antiretroviral therapy for the symptomatic relief of
a. ulcerative colitis.
b. irritable bowel syndrome.
c. Crohn's disease.
d. non-infectious diarrhea.
35. A common adverse reaction associated with crofelemer is
b. QT prolongation.
d. genital discharge.
36. The recommended dosage of crofelemer is
a. 25 mg three times daily.
b. 100 mg three times daily.
c. 125 mg twice daily.
d. 250 mg twice daily.
37. Which new antineoplastic agent is indicated for progressive, metastatic medullary thyroid cancer?
a. cabozantinib malate
c. trametinib dimethyl sulfoxide
d. dabrafenib mesylate
© 2014 by Wolters Kluwer Health | Lippincott Williams & Wilkins.